Claim verdict
Mitochondria
“Elamipretide is an approved anti-ageing therapy.”
This verdict applies to the exact claim above. It is not a verdict on the compound overall, a safety guarantee, or a recommendation to use it.
Registry verdict
Misleading — it holds a narrow accelerated approval for a rare genetic disease.
Why this verdict
- Approval for Barth syndrome does not extend to healthy ageing, performance or general mitochondrial 'optimisation'.
- Trials in broader indications have produced mixed or unsuccessful results.
- Reading a rare-disease approval as an anti-ageing endorsement is one of the most common errors in this space.